BiopharmIQ by Amp
@BiopharmIQ
Catalyst Calendar, Big Mover stocks & model portfolios. Database & tools to help with your biotech investing & BD. not invstmnt advice. http://bpiq.com #biotech
Don't miss out on future PDUFAs & AdComs! 🎯 🗓️ PDUFA events: ⤷ groundbreaking stock milestones ✨ ⤷ often trigger major stock movements 📈 ⤷ ideal for trading & options strategies 💸 Access our free PDUFA Report to see more info! 👇 offers.bpiq.com/pdufa-report
10x scenario $abvx
For context $abvx novel moa (miR-124 upregulation) strong Phase 2b results and smart trial tweaks made this a high-conviction buy for me but it's binary with a huge downside on a miss. Guggenheim scenarios below:
📣 Biotech Stock News 07/22 @ Open $CRDL 15% Database Lock for Phase 2 Trial $CNTB 11% Appoints Industry Veteran to Board $STRO 7% Research Collab. to Advance Standards $CGEM 3% Acceptance of Abstracts for Zipalertinib $BIIB 3% Highlighting Progress in Alzheimer's Disease $EHTH…
So, what we should look at, from $CRDL's acute #myocarditis Ph-2 data? The 2 primary outcome measures of the trial, which were evaluated following 12 weeks of double-blind therapy, consist of cardiac MRI parameters: global longitudinal strain and extra-cellular volume, which…
🚨 $REPL receives CRL for RP1 BLA in Advanced Melanoma ❌ FDA says, IGNYTE trial not “adequate & well-controlled” & lacks substantial evidence of effectiveness. Issues cited: ⚠️ patient heterogeneity ⚠️ & confirmatory trial design flaws (e.g., contribution of components). ✅…
🚨 $REPL & $GSK PDUFAs This Week! See details 👇 1️⃣ $REPL: 🤔 ➯ RP1 + Opdivo (nivolumab) » PDUFA: July 22, 2025 » Advanced Melanoma » BLA 2️⃣ $GSK: 🤔 ➯ Blenrep combinations (BVd & BPd) » PDUFA: July 23, 2025 » Multiple myeloma » BLA 📝 Last Week’s Adcom & PDUFA: $GSK:…
Pull Big Mover Catalysts into Excel! 💻 In this short series we build a stock screener with Python. In part 3 below we pull stock and catalyst data into Excel. Can probably go from part 1 → part 3 in 30 min..
6 Stocks Likely to Move Big on Rare/Genetic Disease Readouts in Q3 ‘25 📈 📉 See 🧵 for more details about each asset/readout 👇 $ARCT (Mid-2025) ARCT-032 / Cystic Fibrosis / Phase 2 $IONS (August 21, 2025) Donidalorsen / Hereditary angioedema / PDUFA $FBIO (September 30,…
🚨 $REPL & $GSK PDUFAs This Week! See details 👇 1️⃣ $REPL: 🤔 ➯ RP1 + Opdivo (nivolumab) » PDUFA: July 22, 2025 » Advanced Melanoma » BLA 2️⃣ $GSK: 🤔 ➯ Blenrep combinations (BVd & BPd) » PDUFA: July 23, 2025 » Multiple myeloma » BLA 📝 Last Week’s Adcom & PDUFA: $GSK:…
🚨 Patent cliffs ahead! With blockbuster IPs expiring in 2027–2028, Big Pharma racing to reshape pipelines & M&A strategies. Great thread from @yaireinhorn 🧵👇
1/Here’s an excellent Financial Times article which accurately describes the problematic situation which many big Pharma companies such as $PFE $JNJ $BMY $ABBV $LLY $MRK $SNY and others are now facing - the upcoming patent cliff scenario. With IP rights which are about to expire…
Biotech Stock Catalyst Watchlist 🚀 🎯 Ph2 & Ph3 readouts in Q3 2025... $NAMS Phase 2a $CRDF Phase 2 $IXHL Phase 2 $ENTX Phase 2 $MLTX Phase 3 $LRMR Phase 2 $KAPA Phase 2 $RAPP Phase 2a $PMVP Phase 2 $ATAI Phase 2b $ARCT Phase 2 $CLNN Phase 2 $AMLX Phase 3 $PRAX…